• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Perrigo launches Marinomed’s Carragelose nasal spray in France and Scandinavia

Marinomed Biotech has announced that it signed a distribution agreement with Perrigo for its Carragelose iota-carrageenan nasal spray, and Perrigo has already launched the product in Finland, Norway, Sweden and France. The OTC nasal spray is being marketed for the prevention of respiratory viruses under the name Physiomer in the Scandinavian countries and as Phytosun Aroms in France.

In July 2021, Marinomed announced that M8 Pharmaceuticals had acquired the rights to Carragelose nasal spray in Brazil and Mexico. Nasal sprays that include Carragelose are now available in numerous countries, including Italy, Austria, Canada, China, and Australia. 

Marinomed CEO Andreas Grassauer commented, “We are proud to partner with Perrigo, an exceptionally experienced organization, to further extend the global reach of our virus blocker Carragelose. With the likely resurgence of respiratory diseases in the upcoming cold season, we are satisfied that Carragelose will be available to even more people providing them protection from viral respiratory infections. The virus-blocking properties of Carragelose can make an important contribution to improving public health and to support hygiene measures against respiratory viruses.”

Perrigo VP International R&D and Innovation Anneleen Spooren said, “Marinomed has shown impressive data on the potential of Carragelose for prevention and self-medication of respiratory infections caused by multiple viruses. Carragelose provides an extremely good fit with our portfolio of effective self-care products. We are happy to now expand our portfolio with this clinically validated virus-blocking and hypertonic product that can provide a fast relief of the symptoms. We are convinced that with Marinomed, we have a strong and reliable science-based partner at our side.”

Read the Marinomed Biotech press release.

Share

published on November 1, 2021

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews